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ICD in Children & Adolescents with Brugada 
Syndrome: ~1 in 4 Patients Receive Appropriate 
Life-Saving Interventions Over a Period of 7 Years, 
Although Inappropriate Shocks and Other Adverse 
Events Occur Relatively Frequently   
Among 35 consecutive patients (aged 13.9±6.2 years). 
over a mean of 88 months, sustained ventricular 
arrhythmias were treated by the ICD in 9 patients (26%), 
including shocks in 8 (23%) and antitachycardia pacing in 
1 patient (3%). Three patients (9%) died in an electrical 
storm. Seven patients (20%) experienced inappropriate 
shocks, and 5 (14%) had device-related complications. 
Aborted sudden cardiac death and spontaneous type I ECG 
were identified as independent predictors of appropriate 
shock occurrence (Gonzalez Corcia MC et al, J Am Coll 
Cardiol 2018;71: 148–57).   
Cardiomyopathy (CM) Patients With LVEF≤35% and 
LBBB Demonstrate Significantly Less LV Functional 
Recovery With Medical Therapy Than Do Those With 
a Narrow QRS / Thus, They Would Benefit From 
Earlier Implantation of a CRT Device 
Among 659 patients with CM, 111 having LBBB 
(17%), 59 wide QRS duration ≥120 ms but not LBBB 
(9%), and 489 narrow QRS duration (74%), adjusted mean 
increase in LVEF over 3-6 months in the 3 groups was 
2.03%, 5.28%, and 8%, respectively (p<0.0001), with no 
different results for interim revascularization and 
myocardial infarction. The combined endpoint of heart 
failure hospitalization or mortality was highest for patients 
with LBBB (Sze et al, J Am Coll Cardiol 2017;71: 306-
17).  
1-Year Follow-Up of PRAGUE-18 Study: Among 
Patients With MI Undergoing Primary PCI, 
Antiplatelet Therapy With Prasugrel or Ticagrelor is 
Associated With Similar Outcomes / Economically 
Motivated, Early Post-Discharge Switch To 
Clopidogrel was not Associated With Increased Risk of 
Ischemic Events  
Among 1,230 patients with acute myocardial 
infarction (MI) treated with primary PCI and randomized 
to prasugrel or ticagrelor, the endpoint (cardiovascular 
death, MI, or stroke at 1 year) occurred in 6.6% of 
prasugrel patients and in 5.7% of ticagrelor patients 
(hazard ratio: 1.167; p = 0.503). No significant differences 
were found in: CV death (3.3% vs 3%), MI (3% vs. 2.5%), 
stroke (1.1% vs 0.7%), all-cause death (4.7% vs. 4.2%), 
definite stent thrombosis (1.1% vs. 1.5%), all bleeding 
(10.9% vs. 11.1%), and TIMI major bleeding (0.9% vs. 
0.7%). The percentage of patients who switched to 
clopidogrel for economic reasons was 34.1% (n=216) for 
prasugrel and 44.4% (n=265) for ticagrelor (p=0.003). 
Patients who were economically motivated to switch to 
clopidogrel had (compared with patients who continued 
the study medications) a lower risk of major CV events; 
however, they also had lower ischemic risk (Motovska Z 
et al, J Am Coll Cardiol 2018;71:371-81).  
DAWN Trial: Among Patients With Acute Stroke Who 
Had Last Been Known to be Well 6 - 24 Hours Earlier 
and Who Had a Mismatch Between Clinical Deficit and 
Infarct, Outcomes for Disability at 90 Days were Better 
With Thrombectomy Plus Standard Care Than With 
Standard Care Alone   
206 ischemic stroke patients with occlusion of the 
intracranial internal carotid artery or proximal middle 
cerebral artery who had last been known to be well 6 -24 
hours earlier and who had a mismatch between the severity 
of the clinical deficit and the infarct volume were enrolled 
(107 assigned to thrombectomy and 99 to controls). At 31 
months, the mean score of disability on the utility-
weighted modified Rankin scale at 90 days was 5.5 in the 
thrombectomy group as compared with 3.4 in the control 
group, and the rate of functional independence at 90 days 
was 49% in the thrombectomy group as compared with 
13% in the control group (posterior probability of 
superiority, >0.999). The rate of symptomatic intracranial 
hemorrhage did not differ significantly between the two 
groups (6% vs 3%), nor did 90-day mortality (19% vs 
18%) (Nogueira RG et al, N Engl J Med 2018; 378:11-21)  
DEFUSE 3 Study: In Acute Ischemic Stroke Due to 
Large-Vessel Occlusion With Favorable Findings on 
Perfusion Imaging, Endovascular Therapy 6-16 Hours 
After Stroke Onset Resulted in Less Disability and a 
Higher Rate of Functional Independence at 3 Months  
This trial was terminated early for efficacy after 182 
patients had been randomized (92 to endovascular-therapy 
and 90 to medical-therapy). Endovascular therapy plus 
medical therapy, as compared with medical therapy alone, 
was associated with a favorable shift in the distribution of 
functional outcomes on the modified Rankin scale at 90 
days (odds ratio, 2.77; P<0.001) and a higher percentage 
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of patients who were functionally independent (45% vs 
17%, P<0.001). The 90-day mortality rate was 14% in the 
endovascular-therapy group and 26% in the medical-
therapy group (P=0.05), and there was no significant 
between-group difference in the frequency of symptomatic 
intracranial hemorrhage (7% and 4%, respectively; P=NS) 
or of serious adverse events (43% and 53%, respectively; 
P=NS) (Albers GW et al, N Engl J Med 2018; 378:708-
718).   
CASTLE-AF: Catheter Ablation for Atrial Fibrillation 
(AF) in Patients with Heart Failure was Associated 
with a Significantly Lower Rate of a Composite End 
Point of Death From any Cause or Hospitalization for 
Worsening Heart Failure than was Medical Therapy 
Among randomized patients to catheter ablation (179 
patients) or medical therapy (184 patients) for AF, over a 
median of 37.8 months, the primary composite end point 
occurred in significantly fewer patients in the ablation 
group than in the medical-therapy group (51 patients or 
28.5% vs 82 patients or 44.6%; hazard ratio-HR, 0.62; 
P=0.007). Significantly fewer patients in the ablation 
group died from any cause (24 or 13.4% vs 46 or 25%; HR, 
0.53; P=0.01), were hospitalized for worsening heart 
failure (37 or 20.7% vs 66 or 35.9%; HR, 0.56; P=0.004), 
or died from cardiovascular causes (20 or 11.2% vs 41 or 
22.3%; HR, 0.49; P=0.009) (Marrouche NF et al, N Engl J 
Med 2018; 378:417-427).   
Significant Association Between Influenza Infection 
and Acute Myocardial Infarction (MI) 
A total of 364 hospitalizations were identified for 
acute MI that occurred within 1 year before and 1 year after 
a positive test result for influenza. Of these, 20 (20 
admissions per week) occurred during the risk interval and 
344 (3.3 admissions per week) occurred during the control 
interval. The incidence ratio of an admission for acute MI 
during the risk interval as compared with the control 
interval was 6.05. No increased incidence was observed 
after day 7. Incidence ratio for acute MI within 7 days after 
detection of influenza B was 10.11, 5.17 for influenza A, 
3.51 for respiratory syncytial virus, and 2.77 for other 
viruses (Kwong JC, N Engl J Med 2018; 378:345-353).   
CABG had a Mortality Benefit Over PCI In Patients 
With Multivessel Disease, Particularly Those With 
Diabetes and Higher Coronary Complexity. No Benefit 
for CABG Over PCI was Seen in Patients With Left 
Main Disease   
Analysis of 11 randomized trials involving 11 518 
patients assigned to PCI (n=5753) or to CABG (n=5765) 
showed a 5-year all-cause mortality of 11.2% after PCI and 
9.2% after CABG (hazard ratio -HR 1.20; p=0.0038). 5-
year all-cause mortality was significantly different 
between the interventions in patients with multivessel 
disease (11.5% after PCI vs 8.9% after CABG; HR 1.28; 
p=0.0019), including in those with diabetes (15.5% vs 
10%; HR 1.48, p=0.0004), but not in those without 
diabetes (8.7% vs 8%; HR 1.08; p=0ꞏ49). SYNTAX score 
had a significant effect on the difference between the 
interventions in multivessel disease. 5-year all-cause 
mortality was similar between the interventions in patients 
with left main disease (10.7% vs 10.5%), regardless of 
diabetes status and SYNTAX score. (Head SJ A et al, 
Lancet 2018;391:939-948).   
TASMINH4 Trial: Self-Monitoring, With or Without 
Telemonitoring, When Used by General Practitioners 
to Titrate Antihypertensive Medication in Individuals 
With Poorly Controlled Blood Pressure, Leads to 
Significantly Lower Blood Pressure Than Titration 
Guided by Clinic Readings   
Among 1182 hypertensive patients, aged >35 years, 
with blood pressure >140/90 mmHg, randomly assigned to 
self-monitoring (n=395), telemonitoring (n=393), or usual 
care group (n=394), of whom 1003 (85%) were analyzed, 
after 12 months, systolic blood pressure was lower in both 
intervention groups compared with usual care (self-
monitoring, 137+16ꞏ7 mm Hg and telemonitoring, 
136+16.1 mm Hg vs usual care, 140.4+16.5). No 
difference between the self-monitoring and telemonitoring 
groups was recorded. Results were similar in sensitivity 
analyses including multiple imputation. Adverse events 
were similar between all three groups (McManus RJ et al, 
Lancet 2018;391: 949-959).   
Excess Mortality, Frequent Heart Failure and 
Undertreatment of Mitral Regurgitation (MR) in a 
Community Setting 
Over 10 years, 1294 community residents (median age 
at diagnosis 77 years) were diagnosed with moderate or 
severe MR by Doppler (prevalence 0.46% overall; 0.59% 
in adults). Left-ventricular ejection fraction (LVEF) <50% 
was frequent (42%), and these patients had a slightly lower 
regurgitant volume than those with an LVEF of >50%. 
Post-diagnosis mortality was mainly cardiovascular in 
nature (51%) and higher than expected for residents of the 
county for age or sex (risk ratio -RR 2.23, p<0ꞏ0001). This 
excess mortality affected all subsets of patients, whether 
they had a LVEF <50% (RR 3.17, p<0ꞏ0001) or >50% 
(1.71, p<0ꞏ0001) and with primary (RR 1.73, p<0ꞏ0001) 
or secondary MR (2.72, p<0ꞏ0001). Even patients with a 
low comorbidity burden combined with favourable 
characteristics such as LVEF of >50% (RR 1ꞏ28, 
p<0ꞏ0017) or primary MR (1.29, p=0ꞏ0030) incurred 
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excess mortality. Heart failure was frequent (mean 64% at 
5 years postdiagnosis), even in patients with LVEF of 
>50% (49% at 5 years postdiagnosis) or in those with 
primary MR (48%). Mitral surgery was ultimately done in 
only 198 (15%) of 1294 patients, of which the predominant 
type of surgery was valve repair (75%). Mitral surgery was 
done in 28 (5%) of 538 patients with LVEF <50% and in 
170 (22%) of 756 patients with LVEF of >50%, and in 34 
(5%) of 723 with secondary MR vs 164 (29%) of 571 with 
primary MR (Dziadzko V et al, Lancet 2018;391:960–9).   
LAA Occlusion May be a Reasonable Option for Stroke 
Prevention in High-Risk Patients With Atrial 
Fibrillation (AF) Ineligible for Anticoagulation / 
However, Procedural Complication Rates are High, 
and Patients Remain at Risk of Serious Adverse Events 
and Death Even After Successful Implant of the 
Amplatzer Amulet LAA Occluder   
Of 83 patients (age 76±8years, 32.5% female, mean 
CHAD2S2-VASc score 4 ±1) offered LAA occlusion, 80 
(95.3%) had previous major bleeding (intracranial in 
59%). LAA occluder implantation with an Amulet device 
was successful in 82 (98.8%), with periprocedural major 
adverse events occurring in 5 (6%) patients (2 device 
embolizations including 1 death, 2 major bleeds). Cardiac 
imaging in 75 (94%) patients 2 months later showed 
device-related thrombus in 1 (1.3%) and minor (<5mm) 
device leaks in 13 (17.1%). Over a median of 12 months, 
3 (3.8%) ischemic strokes, 2 (2.5%) hemorrhagic strokes 
and 5 (6.3%) major extracranial bleeds occurred. All-cause 
mortality was 10%, with most deaths (7, 87.5%) due to 
non-cardiovascular causes (Masoud A et al Heart 
2018;104:594–9).   
Alarming Results for Left Atrial Appendage Closure 
with Lariat and Watchman Devices with Higher 
Complication Rates Reported Post-FDA Approval   
Over 10 years (2006-2016) the Lariat® device was 
implanted in 4,889 patients and the Watchman™ in 5,849 
patients (2,027 prior to FDA approval in March 2015 and 
3,822 patients post-approval). The complication rate 
observed with Watchman was higher than what has been 
reported in recent registries, with higher point estimates for 
pericardial tamponade (0.5% higher), pericardial effusion 
(+0.15%), periprocedural stroke (+0.082%), device 
embolization (+0.28%), and death (+0.21%). In addition, 
the composite endpoint of stroke/TIA, pericardiocentesis, 
cardiac surgery, and death was higher with Watchman 
compared with Lariat (1.93% vs 1.15%, P = 0.001). The 
authors concluded that post-approval new technology 
adoption may be associated with increased complications 
compared with premarket data (Jazayeri M-A et al, J 
Cardiovasc Electrophysiol 2018;29:5–13).   
Meta-analysis of Chronic Total Occlusion (CTO) PCI 
Studies Identifies Predictors Associated With >20% 
Reduction in Clinical/Technical Success: 5 Demo-
graphic Negative Predictors (History of MI/PCI/ 
CABG, PVD and Stroke) / 8 Angiographic Predictors 
(Non-LAD CTO, Multivessel Disease, Bridging 
Collaterals, Moderate-to-Severe Calcification, >45o 
Bending, Tortuous Vessel, Blunt Stump and Ostial 
Lesion)  
Meta-analysis of 61 studies including 69 866 patients 
analyzing rates of CTO PCI success showed >20% 
reduction in the odds of technical and clinical success with 
a prior history of MI, PCI, CABG, stroke/TIA and 
peripheral vascular disease (PVD). Angiographic factors 
were generally stronger predictors of reduced technical 
and clinical success: non-LAD CTOs, multivessel disease, 
presence of bridging collaterals, moderate-to-severe 
calcification, >45 degree vessel bending, tortuous vessel, 
blunt stump and ostial lesions (Wang N et al, Heart 
2018;104:517-24).  
Pooled Analysis of β-Blocker Trials Demonstrates 
Reductions in All-Cause and Cardiovascular Mortality 
by 22% and 25%, Respectively, With no Pooled Effect 
Seen in ACE Inhibitor, ARB and MRA Trials in 
Patients With Heart Failure and Preserved Ejection 
Fraction (≥40%) (HFpEF) 
Data from 25 RCTs comprising 18,101 HFpEF patients 
showed that all-cause mortality was reduced with beta-
blocker therapy compared with placebo (RR: 0.78, 
p=0.008). There was no effect seen with ACE inhibitors, 
aldosterone receptor blockers, mineralocorticoid receptor 
antagonists and other drug classes, compared with placebo. 
Similar results were observed for cardiovascular mortality. 
No single drug class reduced heart failure hospitalization 
compared with placebo (Zheng SL et al, Heart 
2018;104:407-415).   
The Outcomes of Patients With Aortic Stenosis (AS) 
With an AVA of 0.8–0.99 cm2 are Variable and are 
More Precisely Defined by Flow-Gradient Status / The 
Current AVA Cut-Off of 1 cm2 is Inclusive of All Flow-
Gradient AS Subtypes 
Patients with isolated, severe AS and ejection fraction 
≥55% with an AVA of 0.8–0.99 cm2 (n=105) were 
compared with those with an AVA<0.8 cm2 (n=155) and 
1.0–1.3 cm2 (n=81). Patients with an AVA of 0.8–0.99 cm2 
group comprised predominantly normal-flow, low-
gradient (NFLG) AS, while high gradients and low flow 
were more often observed with an AVA<0.8 cm2. The 
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frequency of symptoms was not significantly different 
between an AVA of 0.8–0.99 cm2 and 1.0–1.3 cm2. The 
combined endpoint (death or AVR at or before 3 years) 
was achieved in 71%, 52% and 21% of patients with an 
AVA of 0.8 cm2, 0.8–0.99 cm2 and 1.0–1.3 cm2, 
respectively (p<0.001). Among patients with an AVA of 
0.8–0.99 cm2, NFLG AS was associated with a lower 
hazard (HR=0.40, p=0.001) of achieving the combined 
endpoint with outcomes similar to moderate AS in the first 
1.5 years of follow-up. Patients with high-gradient or low-
flow AS with an AVA of 0.8–0.99 cm2 had outcomes 
similar to those with an AVA<0.8 cm2 (Mehrotra P et al, 
Heart 2018;104:222-229).  
 
Updated Meta-Analysis Demonstrates a Survival 
Benefit of ICD Therapy in Non-Ischemic 
Cardiomyopathy (NICM) 
Meta-analysis of 6 primary prevention trials and 2 
secondary prevention trials representing 3226 NICM 
patients revealed a 24% reduction in overall mortality with 
ICD therapy (RR 0.76) (Beggs SAS et al, Heart 
2018;104:144-150).  
 
High 30-Day Mortality Rate in Both Emergency 
Balloon Aortic Valvuloplasty (eBAV) (33%) and 
Emergency TAVI (eTAVI) Procedures (23.8%) 
Compared to 21.9% Mortality Rate for Elective TAVI 
After eBAV / Primary eTAVI May be a Viable Option, 
Albeit at Unexpected High Rate of Cerebral Events and 
Vascular Complications 
In 5 German centers, 23 patients (logistic Euroscore 
37.7%±18.1) underwent eTAVI and 118 patients 
underwent eBAV (logistic Euroscore 35.3%±20.8). In the 
eTAVI group, immediate procedural mortality was 8.7%, 
compared with 20.3% for the eBAV group (p=0.19). After 
30 days, cardiovascular mortality for the eTAVI group was 
23.8% and for the eBAV group 33% (p=0.40). Of note, the 
elective TAVI performed after eBAV (n=32, logistic 
Euroscore 25.9%±13.9) displayed an immediate 
procedural mortality of 9.4% and a cardiovascular 
mortality after 30 days of 15.6%. Major vascular 
complications were significantly more likely to occur after 
eTAVI (p=0.01) as well as stroke (p=0.01) (Bongiovanni 
D et al, Heart 2018;104:23-29.  
Half of the Deaths Directly Related to a Heart Rhythm 
Disorder Management (HRDM) Procedure Were 
Among the Patients Undergoing Device Implantation 
Procedures, With Cardiac Tamponade Being the Most 
Common Cause of Death  
Among 48 913 patients (age, 65.7±6.6 years; 64% 
male) who underwent a total of 62 065 HRDM procedures, 
the overall mortality and stroke rates in the cohort were 
0.36% and 0.12%, respectively. Patients undergoing lead 
extraction had the highest overall mortality rate at 1.9% 
and stroke rate at 0.62%. Among patients undergoing 
HRDM procedures, 48% of deaths directly related to the 
HDRM procedure were among patients undergoing device 
implantation procedures. Overall, cardiac tamponade was 
the most frequent direct cause of death (40%), and 
infection was the most common indirect cause of death 
(29%). The overall 30-day mortality rate was 0.76%, with 
the highest being in lead extraction procedures (3.08%), 
followed by device implantation procedures (0.94%) (Lee 
JZ et al, Circulation 2018;137:24-33).   
CANVAS: Canagliflozin Reduced Cardiovascular 
(CV) and Renal Outcomes in Diabetic Patients with 
High CV Risk  
Primary prevention participants (N=3486; 34%) were 
younger (63 vs 64 years of age), more often female (45% 
vs 31%), and had a longer duration of diabetes mellitus (14 
vs 13 years) compared with secondary prevention 
participants (N=6656; 66%). The primary end point (CV 
death, nonfatal MI & stroke) event rate was higher in the 
secondary prevention group (36.9 vs 15.7/1000 patient-
years, P<0.001). In the total cohort, the primary end point 
was reduced with canagliflozin compared with placebo 
(26.9 vs 31.5/1000 patient-years; hazard ratio -HR, 0.86; 
P<0.001 for noninferiority, P=0.02 for superiority). Renal 
outcomes (HR, 0.59 vs HR, 0.63; interaction P value = 
0.73) and heart failure hospitalization (HR, 0.68 vs HR, 
0.64; interaction P value=0.91) were similarly reduced in 
the secondary and primary prevention cohorts. Lower 
extremity amputations were similarly increased in the 
secondary and primary prevention cohorts (HR, 2.07 vs 
HR, 1.52; interaction P value=0.63) (Mahaffey KW et al, 
Circulation 2018;137:323-34).  
IRIS Trial: Pioglitazone Was Effective for Secondary 
Prevention of Ischemic Stroke in Nondiabetic Patients 
With Insulin Resistance  
Among 3876 participants (mean age, 63 years; 65% 
male), 377 stroke events were observed in 319 participants 
over a median follow-up of 4.8 years. Pioglitazone was 
associated with a reduced risk for any stroke at 5 years (8% 
vs 10.7% for the placebo group; hazard ratio -HR, 0.75; 
log-rank P=0.01). Pioglitazone reduced risk for ischemic 
strokes (HR, 0.72; P=0.005) but had no effect on risk for 
hemorrhagic events (HR, 1; P=NS) (Yaghi S et al, 
Circulation 2018;137:455-463).   
Takotsubo Cardiomyopathy (TC): Persistent Long-
Term Changes (Heart Failure Phenotype) 
Among 37 patients (middle-aged 64±11 women 97%) 
with history of TC 20 months earlier, the majority (88%) 
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of them had persisting symptoms compatible with heart 
failure (median of 13 in the Minnesota Living with Heart 
Failure Questionnaire) and cardiac limitation on exercise 
testing (reduced peak oxygen consumption, 24±1.3 vs 
31±1.3 mL/kg/min, P<0.001; increased VE/VCO2 slope, 
31±1 vs 26±1, P=0.002). Despite normal left ventricular 
ejection fraction and serum biomarkers, patients with prior 
TC had impaired cardiac deformation indices, increased 
native T1 mapping values, and impaired cardiac energetic 
status (Scally C et al, Circulation 2018;137:1039-48).   
REDUCE LAP-HF 1: In Patients With Heart 
Failure (HF) and EF ≥40%, Implantation of an 
Interatrial Shunt Device (IASD) (8-mm Interatrial 
Communication) Unloaded the Left Atrium and 
Reduced Pulmonary Wedge Pressure (PWP) During 
Exercise to a Greater Extent Than a Sham Control 
Procedure 
In 44 HF patients (aged 70±9 years; 50% female) 
randomized to the IASD (n=22) and control (n=22) groups, 
at 1 month, the IASD resulted in a greater reduction in 
PWP compared with sham control (P=0.028). Peak PWP 
decreased by 3.5±6.4 mm Hg in the treatment group vs 
0.5±5.0 mm Hg in the control group (P=0.14). There were 
no peri-procedural or 1-month major adverse cardiac, 
cerebrovascular, and renal events in the IASD group and 1 
event (worsening renal function) in the control group 
(P=NS) (Feldman T et al; Circulation 2018;137:364-75).   
Community-Based Framingham Heart Study: The 
Lifetime Risk of AF Was 37% After 55 Years of Age/ 
Estimation of Polygenic AF Risk is Feasible and 
Together With Clinical Risk Factor Burden Explains a 
Substantial Gradient in Long-Term AF Risk  
Polygenic risk for AF was derived using a score of 
≈1000 AF-associated single-nucleotide polymorphisms 
(SNPs). Clinical risk factor burden was calculated for each 
individual using a validated risk score for incident AF 
comprised of height, weight, systolic and diastolic blood 
pressure, current smoking status, antihypertensive 
medication use, diabetes mellitus, history of MI, and 
history of heart failure (CHARGE-AF score). 
Among 4606 participants without AF at 55 years of age, 
580 developed incident AF (median follow-up, 9.4 years). 
The lifetime risk of AF >55 years of age was 37.1% and 
was substantially influenced by both polygenic and clinical 
risk factor burden. Among individuals free of AF at 55 
years of age, those in low-polygenic and clinical risk 
tertiles had a lifetime risk of AF of 22.3%, whereas those 
in high-risk tertiles had a risk of 48.2%. A lower clinical 
risk factor burden was associated with later AF onset after 
adjusting for genetic predisposition (P<0.001) (Weng L-C 
et al, Circulation 2018;137:1027-38).  
 
TOPAS-TAVI Registry: Patients With Low-Flow/ 
Low-Gradient Aortic Stenosis (LFLG-AS), TAVI Was 
Associated With Good Early Outcomes, But >1/3 of the 
Patients Survived <2 Years / Pulmonary Disease, 
Anemia and Paravalvular Leaks Were Associated 
With Poorer Outcomes  
Among 287 patients with LFLG-AS undergoing TAVI 
(median STS score 7.7%; mean LVEF 30.1 ± 9.7% and 
transvalvular gradient 25.4 ± 6.6 mmHg), the presence of 
contractile reserve was observed in 45% of patients at 
dobutamine stress echo (DSE), mortality rates were 3.8%, 
20.1%, and 32.3% at 30 days, 1 year, and 2 years, 
respectively. On multivariable analysis, chronic 
obstructive pulmonary disease (p=0.022) and lower 
hemoglobin values (p< 0.001) were associated with all-
cause mortality. Lower hemoglobin values (p=0.004) and 
moderate-to-severe aortic regurgitation post-TAVI (p = 
0.018) were predictors of the composite of mortality and 
rehospitalization due to heart failure. LVEF increased by 
8.3% at 1-year. The absence of contractile reserve at 
baseline DSE was not associated with any negative effect 
on clinical outcomes or LVEF changes at follow-up 
(Ribeiro HB et al, J Am Coll Cardiol 2018; 71:1297-308).   
Abandoning Digoxin Long Overdue: Initiation of 
Digoxin in Patients With AF is Associated With Higher 
Mortality, Regardless of Heart Failure Status / In 
Patients With AF Already Taking Digoxin, Serum 
Levels should be Monitored, with Target <1.2 ng/ml  
Among 17,897 participants in the ARISTOTLE trial, 
5,824 (32.5%) patients were receiving digoxin. Baseline 
digoxin use was not associated with an increased risk of 
death, however, patients with a serum digoxin 
concentration ≥1.2 ng/ml had a 56% increased hazard of 
mortality compared with those not on digoxin. When 
analyzed as a continuous variable, serum digoxin 
concentration was associated with a 19% higher adjusted 
hazard of death for each 0.5-ng/ml increase (p=0.0010); 
these results were similar for patients with and without 
heart failure. Compared with propensity score–matched 
control participants, the risk of death (HR: 1.78) and 
sudden death (HR: 2.14) was significantly higher in new 
digoxin users (Lopes RD C et al, J Am Coll Cardiol 
2018;71:1063-74).   
Meta-Analysis: Compared With Medical Treatment, 
PFO Closure Prevents Recurrent Stroke and TIA But 
Increases Incidence of AF  
Meta-analysis of 4 trials, involving 2531 patients, 
found that PFO closure reduced the risk for the main 
outcome of stroke or TIA (risk difference -RD, −0.029) 
and increased the risk for new-onset AF or AFlu (RD, 
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0.033). The beneficial effect of PFO closure was 
associated with larger interatrial shunts (P= 0.034) (De 
Rosa S et al, Ann Intern Med 2018;168:343-350.).   
Meta-Analysis: In Patients With PFO and Cryptogenic 
Stroke, Transcatheter Device Closure Decreases Risk 
for Recurrent Stroke Compared With Medical 
Therapy Alone / Because Recurrent Stroke Rates are 
Low Even With Medical Therapy Alone and PFO 
Closure Might Affect AF Risk, Shared Decision 
Making is Crucial for this Treatment 
Of 5 trials, 1 was excluded because it used a device that 
is no longer available due to high rates of complications 
and failure. Meta-analysis of 4 trials enrolling 2892 
patients showed that PFO closure decreased the absolute 
risk for recurrent stroke by 3.2% (risk difference, −0.032) 
compared with medical therapy. The treatment strategies 
did not differ in rates of TIA or major bleeding. Closure of 
PFOs was associated with higher rates of new-onset AF 
than medical therapy alone in all trials, but this outcome 
had marked between-trial heterogeneity (I2 = 82.5%) (Shah 
R et al, Ann Intern Med 2018;168:335-42.).  
Over the Last 8 Years, AF Recurrences after Ablation 
Almost Halved / Hypertension, Female Gender, 
Cardioversion 1 Year before Ablation, and AF Lasting 
>2 Years, Increased Risk of Recurrences / Fewer 
Recurrences with Lower CHA2DS2-Vasc Score / 
Patients with Diabetes, Chronic Kidney Disease, and 
Heart Failure Experienced No Improvement  
According with Danish nationwide registers, among 
5425 AF patients undergoing first-time ablation, between 
2005 and 2014, the rates of recurrent AF decreased from 
45% in 2005–2006 to 31% 2013–2014 with the relative 
risk of recurrent AF almost halved with an odds ratio of 
0.57 in 2013–2014 compared with patients undergoing 
ablation in 2005–2006. Female gender, hypertension, AF 
duration >2 years, and cardioversion within 1 year prior to 
ablation were all associated with an increased risk of 
recurrent AF (Pallisgaard JL et al, Eur Heart J 
2018;39:442-9.).  
CVD-REAL 2 Study: Gliflozins (SGLT2 inhibitors) 
Decreased the Risk of Cardiovascular (CV) Outcomes 
(Death, Heart Failure, MI, Stroke) in 408,807 Patients  
In an international study, among 408,807 patients 
(∼27% with established CVD), SGLT-2 inhibitors (SGLT-
2i) were compared with other glucose-lowering drugs 
(oGLD) (235,064 episodes in each group). Use of SGLT-
2i vs oGLDs was associated with lower risk of death (HR 
0.51, P<0.001), heart failure hospitalization-HHF (HR 
0.64, P=0.001), death or HHF (HR 0.60, P<0.001), MI (HR 
0.81, P<0.001) and stroke (HR 0.68, P<0.001). Results 
were directionally consistent both across countries, and 
patient subgroups, including those with and without CVD 
(Kosiborod M et al, J Am Coll Cardiol 2018 March; doi: 
10.1016/j.jacc.2018.03.009).   
High Rho-Kinase Activity in Leucocytes Predicted 
Cardiac Events in Vasospastic Angina (VSA) Patients / 
A Rho-Kinase Activity Value of 1.24 was the Best Cut-
off Level / Combination of the Japanese Coronary 
Spasm Association (JCSA) Risk Score and Rho-kinase 
Activity Further Improved Risk Stratification  
Rho-kinase activity in circulating leucocytes is a 
useful biomarker for diagnosis and disease activity 
assessment of vasospastic angina (VSA). Among 174 
patients with VSA and 50 non-VSA patients, in whom we 
measured Rho-kinase activity in circulating leucocytes, 
followed for a median of 16 months, cardiac events 
(cardiac death, non-fatal MI, and hospitalization for 
unstable angina) occurred in 10 VSA patients (5.7%) but 
in none of the non-VSA patients. Receiver-operating 
characteristic curve analysis showed that Rho-kinase 
activity value of 1.24 was the best cut-off level to predict 
cardiac events in VSA patients (hazard ratio-HR 11.19, 
P = 0.022). Combination of the Japanese Coronary Spasm 
Association (JCSA) risk score and Rho-kinase activity 
significantly improved the prognostic impact in VSA 
patients as compared with either alone (Nihei T et al, Eur 
Heart J 2018; 39:952-9). (Editor’s note: fasudil, a Rho‐
kinase blocker, widely used in patients with subarachnoid 
hemorrhage to prevent intracerebral vasospasm, has also 
been suggested for refractory VSA).   
Less Dementia with Oral Anticoagulation in AF 
Among 444,106 AF patients, those on anticoagulant 
had 29% lower risk of dementia (hazard ratio - HR 0.71). 
Direct comparison between new oral anticoagulants and 
warfarin showed no difference (HR 0.97) (Friberg L & 
Rosenqvist M, Eur Heart J 2018;39:453-60).  
Important Review and Other Articles   
● Obesity (Gadde KM et al, J Am Coll Cardiol 2018;71:69-84), 
● 2017 ESC Guidelines for Peripheral Arterial Diseases 
(Aboyans V et al, Eur Heart J 2018;39:763-816),   
Out-of-hospital cardiac arrest (Lancet 2018; 391:970-9, 980-8, 
989-98),  
● Takotsubo cardiomyopathy (Dawson DK, Heart 2018;104:96-
102),  
● Non-surgical septal reduction in hypertrophic cardiomyopathy 
(Cooper RM et al, Heart 2018;104:73-83),  
● Radial artery for PCI or surgery (Gaudino M et al, J Am Coll 
Cardiol 2018; 71:1167-75),  
● Cryptogenic stroke and PFO (Mojadidi MK et al, J Am Coll 
Cardiol 2018;71:1035-43),  
